BioSpace News Archive

MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) and Incyte (Nasdaq:INCY) today announced that Monjuvi® (tafasitamab-cxix), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, has been included in the latest National Comprehensive Cancer Network® Clinical Practice Guidelines (NCCN Guidelines®)

MichBio welcomes Uma Sharma, PhD Chief Scientific Officer at MMS Holdings and Ron Perry Vice President and General Manager at Emergent BioSolutions to the Board of Directors. Uma Sharma, PhD was appointed in mid-August to complete a term expiring in December 2021. As the CSO of MMS Holdings, she is a hands-on leader focused on guiding sponsors on clinical strategy and colleagues through an inclusive leadership mode

‒ Achieved primary endpoint ‒ ‒ Unremarkable results in key NASH measures ‒ ‒ Company discontinuing further development ‒

CureVac N.V. (“CureVac” or the “Company”), a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced today the closing of its initial public offering of 15,333,332 common shares

Quest Diagnostics, the world’s leading provider of diagnostic information services, announced that its Board of Directors declared a quarterly cash dividend of $0.56 per share, payable on October 21, 2020 to shareholders of record of Quest Diagnostics common stock on October 6, 2020.

The Terasaki Institute for Biomedical Innovation is pleased to welcome Maurizio Vecchione as its Chief Innovation Officer.

The only FDA-indexed, pharmaceutical grade, extended-release buprenorphine available [18-August-2020] NORTH BRUNSWICK, N.J. , Aug. 18, 2020 /PRNewswire/ -- Fidelis Pharmaceuticals today announced the availability of new Ethiqa XR (buprenorphine extended-release injectable suspension) 1.3 mg/mL. Ethiqa XR is the only pharmaceutical grade extended-release buprenorphine

QIAseq SARS-CoV-2 Primer Panel converts viral RNA samples into libraries ready for sequencing QIAGEN Digital Insights solutions support COVID-19 drug, vaccine and epidemiology research HILDEN, Germany & GERMANTOWN, Md.--( BUSINESS WIRE )-- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) launched the innovative QIAseq SARS-CoV-2 Primer Panel for next-generation sequencing (NGS) of the novel coronavirus genome, along with int

Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases, today provided a business update and announced financial results for the second quarter of 2020

Premier Health of America Inc. (formerly known as Physinorth Acquisition Corporation Inc.) (TSXV: PHA) (the “Corporation”), a leading Canadian Healthtech company, announces it has filed its interim consolidated financial statements and interim MD&A for its fiscal third quarter ended June 30, 2020.